Other Names | Tesamorelin |
MF | C211H366N72O67S1 |
EINECS No. | N/M |
Place of Origin | China |
Grade Standard | Medicine Grade |
Usage | Animal Pharmaceuticals |
Product Name | Tesamorelin |
Model Number | TOP |
Storage | ry and cool place |
Color | White Color |
Package | Drum |
Function | Body |
Shelf life | 2 years |
OEM | OEM/ODM |
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group. Tesamorelin (also known as Egrifta) is a synthetic form which is used in the treatment of HIV-associated lipodystrophy.
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in pla-c-ement of body fat, including wasting and fat accumulation, and changes in metabolism.
function in cognitively normal and mildly impaired older individuals in a pla-c-ebo-controlled trial, also reported greater subjective improvement in cognition relative to the pla-c-ebo group.
Studied as a way to reduce excess deep belly fat, the synthetic human growth hormone releasing factor called tesamorelin (Egrifta) was approved by the in November 2010 and has been available since January 2011. Results from a 52-week study of 816 people showed 18% less deep belly fat in those on tesamorelin than those taking pla-c-ebo
Other Names | Tesamorelin |
MF | C211H366N72O67S1 |
EINECS No. | N/M |
Place of Origin | China |
Grade Standard | Medicine Grade |
Usage | Animal Pharmaceuticals |
Product Name | Tesamorelin |
Model Number | TOP |
Storage | ry and cool place |
Color | White Color |
Package | Drum |
Function | Body |
Shelf life | 2 years |
OEM | OEM/ODM |
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group. Tesamorelin (also known as Egrifta) is a synthetic form which is used in the treatment of HIV-associated lipodystrophy.
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in pla-c-ement of body fat, including wasting and fat accumulation, and changes in metabolism.
function in cognitively normal and mildly impaired older individuals in a pla-c-ebo-controlled trial, also reported greater subjective improvement in cognition relative to the pla-c-ebo group.
Studied as a way to reduce excess deep belly fat, the synthetic human growth hormone releasing factor called tesamorelin (Egrifta) was approved by the in November 2010 and has been available since January 2011. Results from a 52-week study of 816 people showed 18% less deep belly fat in those on tesamorelin than those taking pla-c-ebo